文献

J-GLOBAL ID：201702231177637106   整理番号：17A1561167

miR 491 3P/Sp3/ABCB1軸は肝細胞癌の多剤耐性を減弱する【Powered by NICT】

The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma

著者 (21件)： Zhao Yang (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Zhao Yang (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Qi Xinming (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Qi Xinming (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Chen Jing (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Chen Jing (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Wei Wenxin (Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China) ,  Yu Cunzhi (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Yu Cunzhi (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Yan Hong (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Yan Hong (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Pu Mengfan (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Pu Mengfan (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Li Yu (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Li Yu (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Miao Lingling (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Miao Lingling (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Li Chunzhu (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Li Chunzhu (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China) ,  Ren Jin (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China) ,  Ren Jin (Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, University of Chinese Academy of Sciences, Beijing 100049, China)
資料名： Cancer Letters  (Cancer Letters)
巻： 408  ページ： 102-111  発行年： 2017年 
JST資料番号： E0606B  ISSN： 0304-3835  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 肝細胞癌(HCC)の治療と予後における主な障害の一つとして,多剤耐性(MDR)は化学療法剤の細胞内濃度を低減するための原因となる薬剤排出ポンプP糖蛋白質(P gp/ABCB1)の過剰発現と関連している。本研究では,HCCにおけるABCB1介在多剤耐性におけるmiRの491 3pの新しい役割を発見し,miR Oの491 3pは直接それらの3′-UTRを標的とすることによりABCB1とその転写因子Sp3の発現をダウンレギュレーションした基礎となる機構を明らかにした。を過剰発現するABCB1またはSp3はmiR 491 3Pによって誘起されたHep3B細胞における化学療法剤に対する感受性を逆転し,HCCの薬剤感受性の増強に重要な役割を果たしているmiR491 3P/Sp3/ABCB1調節ループを確認した。一方,miR 491 3Pの発現レベルは,HCC細胞系および臨床試料におけるABCB1およびSp3のそれと逆相関した発見は,臨床使用におけるmiR Oの491 3pの可能性を指摘した。要約すると,著者らの結果は,HCCにおけるMDRの調節におけるmiRの491 3pの重要な役割を明らかにし,癌細胞のMDRを調節するための治療戦略としてのmiR Oの491 3pの潜在的応用を示唆した。Copyright 2017 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： 転写因子 ,  *肝細胞癌 ,  P糖タンパク質 ,  腫瘍細胞 ,  *多剤耐性 ,  薬剤感受性 ,  治療計画 ,  ダウンレギュレーション
準シソーラス用語： 細胞株 ,  Hep3B細胞 ,  *Sp3転写因子 ,  過剰発現 ,  薬剤排出ポンプ ,  細胞内濃度 ,  化学療法薬 , 【Automatic Indexing@JST】

著者キーワード (5件)： 肝細胞癌 ,  ABCB1 ,  Sp3 ,  miR 491 3P ,  多剤耐性

分類 (4件)： 腫ようの化学・生化学・病理学  (GE02030N) ,  遺伝子発現  (EC02040Q) ,  消化器の腫よう  (GH04000D) ,  抗腫よう薬の基礎研究  (GW16010A)

タイトルに関連する用語 (6件)： MIR ,  Sp3 ,  ABCB1 ,  肝細胞癌 ,  多剤耐性 ,  減弱